Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel
NASDAQ:CMND

Clearmind Medicine Q3 2026 Earnings Report

Clearmind Medicine logo
$6.00 +0.28 (+4.90%)
Closing price 10/5/2026 03:59 PM Eastern
Extended Trading
$5.99 -0.01 (-0.17%)
As of 07:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings History

Clearmind Medicine EPS Results

Actual EPS
-$4.56
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Clearmind Medicine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Clearmind Medicine Announcement Details

Quarter
Q3 2026
Date
9/10/2026
Time
After Market Closes
Conference Call Date
Thursday, September 10, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Clearmind Medicine's Q3 2026 Press ReleasePress Release
(6-K)

Clearmind Medicine Earnings Headlines

Clearmind Reports U.S. Patent Applications For Drug Combinations In Mental Health
September 26, 2026  |  rttnews.comhttps://www.rttnews.com/3694084/clearmind-reports-u-s-patent-applications-for-drug-combinations-in-mental-health.aspx
Clearmind Medicine Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
September 24, 2026  |  marketscreener.comM
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
October 6 at 1:00 AM  |  Profits Run (Ad)
NeuroThera Labs Inc. And Clearmind Medicine Inc. Highlight Enhancement Of U.S. Patent Portfolio Through Collaboration Covering LSD, Ketamine And Ibogaine Combinations
September 23, 2026  |  marketscreener.comM
Clearmind Medicine Announces U.S. Publication of Patent Applications Covering LSD, Ketamine and Ibogaine Combinations with N-Acylethanolamines
September 23, 2026  |  quiverquant.comQ
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367404/0/en/clearmind-enhances-u-s-ip-presence-with-publication-of-three-patent-applications-covering-lsd-ketamine-and-ibogaine-combinations.html
See More Clearmind Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clearmind Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearmind Medicine and other key companies, straight to your email.

About Clearmind Medicine

Clearmind Medicine (NASDAQ:CMND) is a biotechnology company focused on developing psychedelic-derived therapeutics for behavioral and mental health disorders. Its research programs are designed to address conditions with significant unmet medical needs, including alcohol use disorder and binge-related behaviors.

The company’s pipeline includes investigational compounds based on novel psychedelic molecules, including 5-methoxy-2-aminoindane (MEAI). Clearmind is studying these compounds for their potential to reduce harmful consumption patterns and support improved mental health outcomes. Its activities include preclinical research, drug discovery and the advancement of candidates toward clinical development.

Clearmind Medicine is incorporated in Canada and has conducted research and development activities internationally, including in Israel. The company’s programs remain investigational, and its product candidates have not been approved for commercial sale by regulatory authorities.

View Clearmind Medicine Profile
Earnings Tools